Share on StockTwits

Avitar (OTCMKTS:AVTI) and COLOPLAST A/S/ADR (OTCMKTS:CLPBY) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Institutional & Insider Ownership

0.1% of COLOPLAST A/S/ADR shares are owned by institutional investors. 7.4% of Avitar shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings for Avitar and COLOPLAST A/S/ADR, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avitar 0 0 0 0 N/A
COLOPLAST A/S/ADR 0 1 0 0 2.00


COLOPLAST A/S/ADR pays an annual dividend of $0.08 per share and has a dividend yield of 0.7%. Avitar does not pay a dividend. COLOPLAST A/S/ADR pays out 27.6% of its earnings in the form of a dividend.


This table compares Avitar and COLOPLAST A/S/ADR’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Avitar N/A N/A N/A
COLOPLAST A/S/ADR 23.28% 70.05% 32.97%

Volatility & Risk

Avitar has a beta of -0.04, indicating that its stock price is 104% less volatile than the S&P 500. Comparatively, COLOPLAST A/S/ADR has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500.

Valuation & Earnings

This table compares Avitar and COLOPLAST A/S/ADR’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Avitar N/A N/A N/A N/A N/A
COLOPLAST A/S/ADR $2.63 billion 9.49 $614.43 million $0.29 39.83

COLOPLAST A/S/ADR has higher revenue and earnings than Avitar.


COLOPLAST A/S/ADR beats Avitar on 7 of the 9 factors compared between the two stocks.

Avitar Company Profile

Avitar, Inc. is a holding company which through its subsidiaries designs, develops, manufactures, and markets diagnostic test products and proprietary hydrophilic polyurethane foam disposables for medical, diagnostics, dental, and consumer applications in the United States. It offers ORALscreen 4 and ORALscreen DRUGOMETER, the oral fluid-based onsite assay systems, for detecting drugs of abuse, such as opiates, including heroin, morphine, codeine, and synthetic opiates comprising oxycocone-oxycontin, percoset, and hydrocodone-vicodin; cocaine such as crack; marijuana; and methamphetamines, including meth and ecstasy. The company also provides foam disposable products including medical-grade hydrophilic polyurethane foam disposables such as wound dressings comprising Hydrasorb, a wound dressing product for exudating wounds; and various custom foam products comprising a sinus dressing and a device used by astronauts for relieving ear pressure while in a pressurized space suit. In addition, it develops specialty wound dressings for the cardiac catheter lab market, as well as the Illizarov Dressing used for dressing external bone fixators in orthopedic procedures. The company markets its products and services to employers, diagnostic test distributors, medical supply companies, governmental agencies, schools, and corporations through direct sales force and strategic partners, as well as through a network of distributors. Avitar, Inc. was founded in 1986 and is based in Canton, Massachusetts with Additional office in Calgary, Canada.

COLOPLAST A/S/ADR Company Profile

Coloplast A/S develops and markets intimate healthcare products and services worldwide. The company operates through three segments: Chronic Care, Interventional Urology, and Wound & Skin Care. It provides ostomy care products, including SenSura Mio, which provides fit to individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as SpeediCath catheters that offer catherisation for both genders; Peristeen, an anal irrigation system for controlled emptying of the bowels; and Conveen Active urine bags. In addition, it provides wound care products, such as foam dressings under the Biatain brand and hydrocolloid dressing under the Comfeel brand, as well as skin care products, such as bathing and cleansing products, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. It offers disposable products that include prostate catheters and stents used before, during, and after surgery under the Porgès brand; vaginal slings to restore continence; synthetic mesh products to treat weak pelvic floor; and penile implants for men. The company supplies its products to hospitals, institutions, wholesalers, and pharmacies; and directly to users. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.

Receive News & Ratings for Avitar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avitar and related companies with's FREE daily email newsletter.

Latest News

Investment Analysts’ Price Target Changes for October, 14th
Investment Analysts’ Price Target Changes for October, 14th
Civic  Market Cap Achieves $26.92 Million
Civic Market Cap Achieves $26.92 Million
TRAXIA Tops 24-Hour Trading Volume of $207.00
TRAXIA Tops 24-Hour Trading Volume of $207.00
TOP  Price Hits $0.0022
TOP Price Hits $0.0022
Syndax Pharmaceuticals  Stock Rating Upgraded by Zacks Investment Research
Syndax Pharmaceuticals Stock Rating Upgraded by Zacks Investment Research
Laboratory Corp. of America  Stock Rating Upgraded by Zacks Investment Research
Laboratory Corp. of America Stock Rating Upgraded by Zacks Investment Research

© 2006-2019 Zolmax.